Glioblastoma (GBM) is the most aggressive and frequently
occurring
type of malignant brain tumor in adults. The initiation, progression,
and recurrence of malignant tumors are known to be driven by a small
subpopulation of cells known as tumor-initiating cells or cancer stem
cells (CSCs). GBM CSCs play a pivotal role in orchestrating drug resistance
and tumor relapse. As a prospective avenue for GBM intervention, the
targeted suppression of GBM CSCs holds considerable promise. In this
study, we found that rocaglates, compounds which are known to inhibit
translation via targeting of the DEAD-box helicase
eIF4A, exert a robust, dose-dependent cytotoxic impact on GBM CSCs
with minimal killing of nonstem GBM cells. Subsequent optimization
identified novel rocaglate derivatives (rocaglate acyl sulfamides
or Roc ASFs) that selectively inhibit GBM CSCs with nanomolar EC50 values. Furthermore, comparative evaluation of a lead CSC-optimized
Roc ASF across diverse mechanistic and target profiling assays revealed
suppressed translation inhibition relative to that of other CSC-selective
rocaglates, with enhanced targeting of the DEAD-box helicase DDX3X,
a recently identified secondary target of rocaglates. Overall, these
findings suggest a promising therapeutic strategy for targeting GBM
CSCs.